AMGN compared with RLAY: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

RLAYRelay Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

RLAYRelay Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No shared counterparties.

Only RLAY 3

—D.E. Shaw Researchunlistedsupplier

—Elevar Therapeuticsunlistedcustomer

—Genentechunlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

AMGNAmgen Inc

461.49▼−3.55%· post 459.05· delayed

Mkt cap$258.8BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

RLAYRelay Therapeutics, Inc.

16.95▼−6.00%· post 16.95· delayed

After hoursNov 5 '26delayed

Mkt cap$4.0BRevenue$350,000Q2 FY26Revenue—

Compare

After hoursNov 5 '26delayed

AMGNAmgen Inc

RLAYRelay Therapeutics, Inc.

461.49▼−3.55%post 459.05delayed

Price

16.95▼−6.00%post 16.95delayed

$258.8B

Mkt cap

$4.0B

Q3 FY26$10.4B

Revenue

$350,000Q2 FY26

FY25$36.8B

Revenue

—

AMGN461.49▼−3.55%vsRLAY16.95▼−6.00%After hoursNov 5 '26delayed